Joel Mason, MD
Gastroenterology · Boston, MANPI 1164539292
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $70,285 of the $84,141 with a category attached, or 83.5%. Takeda Pharmaceuticals U.S.A., Inc. accounts for 90.2% of it on its own, with 8 other manufacturers making up the rest. Among gastroenterology clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 70 payments — averaging $1202.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$76K
- Shire North American Group Inc$8K
- Johnson & Johnson$221
- Bristol Myers Squibb$90
- UCB, Inc.$26
- Sanofi$21
- plus $47 from 3 others
Across 160 payments — averaging $3999.24 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$555K
- Shire North American Group Inc$85K
What the payments were for
- Consulting fees$70,28584%
- Travel & lodging$12,23215%
- Food & beverage$1,6242%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 36 | $75,929 |
| Shire North American Group Inc | 11 | $7,807 |
| Johnson & Johnson | 13 | $221 |
| Bristol Myers Squibb | 4 | $90 |
| UCB, Inc. | 2 | $26 |
| Sanofi | 1 | $21 |
| AbbVie | 1 | $18 |
| Gilead | 1 | $16 |
| Merck | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GATTEX$76,437
How this compares
$84,141 in reported general payments places this provider in the 95th percentile of 579 gastroenterology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Pantoprazole Sodium | 100 | $6,110 |
| Sodium Chloride0.9 % Sodium Chloride | 62 | $2,594 |
| Metformin Hcl | 13 | $2,109 |
| Diphenhydramine Hcl | 49 | $2,090 |
| Ondansetron HclOndansetron Hcl/Pf | 48 | $1,719 |
| Levocarnitine | 36 | $1,350 |
| CarnitorLevocarnitine | 24 | $983 |
| Heparin SodiumHeparin Sodium,porcine | 13 | $575 |
| FamotidineFamotidine/Pf | 21 | $518 |
| Ceftazidime | 50 | $259 |
| Famotidine | 11 | $178 |
| Ondansetron OdtOndansetron | 12 | $165 |
| Vancomycin Hcl | 30 | $139 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Boston
- Hiroyuki AiharaBoston$728K
- Jessica AllegrettiBoston$696K
- John LeungBoston$682K
- Ramnik XavierBoston$567K
- Adam CheifetzBoston$512K
- Carlo TraversoBoston$447K
- Tyler BerzinBoston$215K
- Marvin RyouBoston$162K
- Nneka UfereBoston$153K
- Christopher ThompsonBoston$127K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.